Literature DB >> 8387049

Therapeutic prospects of bradykinin receptor antagonists.

J N Sharma1.   

Abstract

1. Bradykinin and related kinins may act on four types of receptors designated as B1, B2, B3 and B4. It seems that the B2 receptors are most commonly found in various vascular and non-vascular smooth muscles, whereas B1 receptors are formed in vitro during trauma, and injury, and are found in bone tissues. 2. These BK receptors are involved in the regulations of various physiological and pathological processes. 3. The mode of kinin actions are based upon the interactions between the kinin and their specific receptors, which can lead to activation of several second-messenger systems. 4. Recently, numerous BK receptors antagonists have been synthesized with prime aim to treat diseases caused by excessive kinin production. 5. These diseases are RA, inflammatory diseases of the bowel, asthma, rhinitis and sore throat, allergic reactions, pain, inflammatory skin disorders, endotoxin and anaphylactic shock and coronary heart diseases. 6. On the other hand, BK receptor antagonists could be contraindicated in hypertension, since these drugs may antagonize the antihypertensive therapy and/or may trigger the hypertensive crisis. 7. It is worth suggesting that the BK receptor agonists might be useful antihypertensive drugs.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8387049     DOI: 10.1016/0306-3623(93)90302-e

Source DB:  PubMed          Journal:  Gen Pharmacol        ISSN: 0306-3623


  5 in total

1.  Pro-inflammatory properties of the kallikrein-kinin system: potential for new drug therapy.

Authors:  J N Sharma; A P Yusof
Journal:  Inflammopharmacology       Date:  1998       Impact factor: 4.473

2.  Evidence for activation of the tissue kallikrein-kinin system in nociceptive transmission and inflammatory responses of mice using a specific enzyme inhibitor.

Authors:  J A da S Emim; C Souccar; M S de A Castro; R O Godinho; M H Cezari; L Juliano; A J Lapa
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

3.  Modifications in tissue kallikrein activity with indomethacin and prednisolone treatment in arthritic rats.

Authors:  J N Sharma
Journal:  Inflammopharmacology       Date:  2010-02-27       Impact factor: 4.473

Review 4.  The kinin system in hypertensive pathophysiology.

Authors:  Jagdish N Sharma
Journal:  Inflammopharmacology       Date:  2012-04-17       Impact factor: 4.473

5.  The kinin antagonist hoe 140 reduces acute paw oedema in rats caused by carrageenan, bradykinin and kaolin.

Authors:  J N Sharma; A P Yusof; K J Wirth
Journal:  Inflammopharmacology       Date:  1998       Impact factor: 5.093

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.